Wechselwirkungen · Ceprotin
CEPROTIN 1,000 IU powder and solvent for solution for injection · Abschnitt 4.5 · PDF-Seite 13
HOS-091626 · Präparat HOS-084373
In patients starting treatment with oral anticoagulants belonging to the class of vitamin K antagonists (e.g. warfarin), a transient hypercoagulable state may arise before the desired anticoagulant effect becomes apparent. This transient effect may be explained by the fact that protein C, itself a vitamin K dependent plasma protein, has a shorter half-life than most of the vitamin K dependent proteins (i.e. II, IX and X). Subsequently, in the initial phase of treatment, the activity of protein C is more rapidly suppressed than that of the procoagulant factors. For this reason, if the patient is switched to oral anticoagulants, protein C replacement must be continued until stable anticoagulation is obtained. Although Warfarin-induced skin necrosis can occur in any patient during the initiation of oral anticoagulant therapy, individuals with congenital protein C deficiency are particularly at risk. (See section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): vitamin K (HOS-091176) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-02-02T11:03:00Z · SHA-256 0185892452ffa6635104e46bba70ecf185fd6943b4e4c738d1e66a6dd19ed835 · Passage 7298f1e3d8ee23306a49661d8634fa0571f5632d57a880a812537d83fb5fb3d8 · Zeichen 108–1036 im Abschnitt